title: Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
abstract: BACKGROUND
  Prolonged exposure to a selective progesterone receptor modulator (ulipristal acetate) in a patient with benign metastasizing leiomyoma did not result in endometrial hyperplasia or neoplasia.
  
  
  METHODS
  A woman with history of benign metastasizing leiomyoma underwent medical treatment for 5 years with ulipristal acetate. Endometrial biopsies were performed at established intervals to monitor for intraepithelial neoplasia or progesterone receptor modulator-associated endometrial changes (PAECs). The patient tolerated UPA therapy well; there was no evidence of hyperplasia or proliferative changes associated with progesterone-associated endometrial changes.
  
  
  CONCLUSIONS
  In this case prolonged exposure to ulipristal acetate did not result in premalignant or malignant endometrial pathology.
authors.forename: Gary
authors.initials: G
authors.lastname: Levy
authors.forename: John
authors.initials: J
authors.lastname: Elkas
authors.forename: Alicia Y
authors.initials: AY
authors.lastname: Armstrong
authors.forename: Lynnette K
authors.initials: LK
authors.lastname: Nieman
mesh_terms: D000328:Adult; D001706:Biopsy; D002278:Carcinoma in Situ / Q000473:pathology; D004714:Endometrial Hyperplasia / Q000473:pathology; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009649:Norpregnadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011230:Precancerous Conditions; D011980:Receptors, Progesterone / Q000187:drug effects*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D009649:Norpregnadienes; D011980:Receptors, Progesterone; C555622:ulipristal acetate